Risk Management · Section 9.10
~5 min read · The Drug Safety Coach — Global PV Career Course
Key points
Full text
Every other part of the RMP this module has covered is written for a technically fluent audience — regulators, medical reviewers, PV professionals — who share the vocabulary this entire course has been building. Part VI, the Public Summary, deliberately breaks that pattern: it’s written specifically for patients and the general public, and getting that register right is a genuinely distinct skill from everything else this course has covered, even though it’s drawing on exactly the same underlying content.
Plain language here means more than avoiding jargon, though that’s part of it — technical terms that appear unexplained everywhere else in the RMP (disproportionality, causality assessment, expectedness) simply can’t appear in the Public Summary without being either avoided entirely or explained in genuinely accessible terms. It also means favouring concrete framing over abstract: "this medicine can, in rare cases, cause liver problems, which is why your doctor will check your liver function with a blood test" communicates something a patient can actually act on, in a way that a more clinically precise but abstract statement about hepatotoxicity incidence rates doesn’t.
The same objectivity discipline Module 5 built for individual case narratives applies here too, in a different but recognisable form: a Public Summary needs to be accurate without being alarmist, and reassuring without minimising genuine risk. Overstating risk can cause patients to avoid a medicine that genuinely benefits them; understating it can leave them unprepared to recognise a warning sign they should actually watch for. That balance is a harder writing problem than it might first appear, precisely because it has to be struck without the hedged, carefully qualified language the rest of the RMP can rely on.
It’s worth sitting with the practical reality this creates: for the overwhelming majority of patients taking a given medicine, the Public Summary is the only part of the entire RMP they will ever actually read, if they read any of it at all. Every other part of this module’s six-part structure exists, in a real sense, to inform and justify what ends up in this one, disproportionately important section — which is exactly why its clarity deserves as much deliberate craft as the technical rigor that goes into the sections regulators and reviewers will actually scrutinise.
Note
Test for a genuinely accessible Public Summary: could someone with no medical or regulatory background read it and correctly understand what risks exist and what’s being done about them, without needing to look up a single term? If a sentence from Part II’s Safety Specification could be dropped into the Public Summary unchanged, it almost certainly hasn’t been translated into plain language yet.
Quick check
Test yourself before moving on — no pressure, just click an answer.
1. Why does this lesson argue the Public Summary’s clarity matters "disproportionately to its length" within the overall RMP?